WCLC 2023 | MET-targeting therapies for NSCLC

Chul Kim, MD, MPH, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, discusses whether MET-targeting therapies might be an effective therapeutic option in the treatment of MET fusion-positive non-small cell lung cancer (NSCLC). Dr Kim also highlights the need for high-quality data from prospective studies in order to improve understanding of MET-targeting efficacy. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.